Topical finasteride in 2025: leading brands, how they work and safety guidance

A growing number of men seeking to slow or reverse pattern hair loss are turning to topical finasteride formulations that aim to reduce scalp levels of dihydrotestosterone (DHT) while limiting systemic exposure. A 2025 product review compiled by The Post highlights several prescription-strength topical options that combine finasteride with minoxidil and other supporting compounds, and dermatologists say the approach can be effective for many patients when used consistently.

Male pattern hair loss affects a large share of the population; the American Hair Loss Association estimates about 85 percent of men will experience some degree of hair loss by age 50. Finasteride is one of the few medications that directly targets a hormonal pathway implicated in follicle miniaturization by inhibiting the enzyme 5-alpha reductase, which converts testosterone into DHT. Board-certified dermatologist Nazanin Saedi told The Post that reducing DHT helps preserve hair follicles and can slow hair loss or promote regrowth.

The Post’s roundup identified Ulo, Happy Head, hims, an Amazon-based DHT blocker serum and Keeps as among the most prominent topical options in 2025. The products differ in finasteride and minoxidil concentrations, delivery format and added ingredients intended to enhance absorption or follicle stimulation. Manufacturers and clinicians stress that the effectiveness of any regimen depends on consistent application and, in many cases, ongoing prescriptions and follow-up with a provider.

Ulo’s Finasteride + Minoxidil Plus was named best overall. The formulation contains 0.2 percent finasteride and 7 percent minoxidil, along with supporting compounds such as cetirizine, melatonin, caffeine and retinoic acid, which the company says enhance follicle stimulation and absorption. Ulo pairs its topical product with provider matching and ongoing support for patients pursuing hair regrowth. The Post noted results may be seen within three to six months, with further improvement up to one to two years of continued use. Ulo recommends twice-daily application for optimal results, though once-a-day use may still be effective for some users.

Happy Head’s prescription-strength topical solution was cited as the best runner-up. Its formula contains 0.3 percent finasteride and 8 percent minoxidil and is dispensed with a calibrated dropper for precise application. Happy Head offers a complimentary consultation with a board-certified dermatologist when users sign up; the company and reviewers emphasize that best results require consistent, long-term use. Higher minoxidil concentrations can increase the risk of scalp irritation for some users.

hims markets a quick-drying topical spray that combines 0.3 percent finasteride with 6 percent minoxidil. The spray format is intended to be easy and fast to apply, though the company and reviewers note it can be harder to target specific small patches of hair loss. Some users report mild scalp dryness or irritation as side effects, and clinicians advise monitoring for local reactions.

For individuals who prefer a non-prescription or plant-based approach, The Post included an Amazon-sold DHT blocker hair serum formulated from herbal and oil ingredients such as organic argan oil, pumpkin seed and saw palmetto oil. The product does not contain finasteride and therefore may be less effective for hormone-driven hair loss, though some users reported decreased shedding or early regrowth after about three months. The serum is produced under U.S. Good Manufacturing Practice standards and marketed to both men and women.

Keeps’ topical gel was noted as the most affordable finasteride option among the reviewed brands. It combines 0.25 percent finasteride with 5 percent minoxidil and is presented as a lower-dose, lower-cost alternative. Review images accompanying Keeps’ product listings show instances of visible regrowth after consistent application, but the company’s gel requires pumping into the hands before applying, which some users find messy.

Dermatologists emphasize important safety considerations. Saedi told The Post that finasteride is FDA-approved for men with androgenetic alopecia and is contraindicated in women of childbearing potential because of the risk of birth defects. Some research has examined off-label use for postmenopausal women, but that application is not widely approved and is considered off-label by dermatologists. For women, alternative therapies such as spironolactone are frequently used off-label to address hormonally influenced hair loss.

Topical formulations are designed to concentrate the active drug at the scalp and thereby reduce systemic absorption. Saedi said this typically limits adverse effects to local reactions such as scalp redness or itchiness. Oral finasteride, by contrast, circulates systemically and has been associated in some patients with decreased libido and erectile dysfunction. Saedi and other clinicians advise patients to weigh potential benefits and risks with a prescribing provider and to report any side effects promptly.

Clinical response to finasteride varies by individual, and discontinuing treatment usually results in a return to previous hair-loss progression. Saedi told The Post that finasteride is effective for many patients but that long-term, consistent use is generally necessary to maintain gains. Most product pages and clinicians cited timelines of several months before meaningful improvement, commonly noting initial results within three to six months and continued gains with ongoing therapy.

The reviewed topical products are generally available only with a prescription or after an online consultation with a licensed clinician. Companies offering telehealth assessments said they provide prescription management and guidance on application and follow-up. Patients and clinicians alike say monitoring for side effects and periodic evaluation of progress are standard parts of a finasteride-based regimen.

Consumers considering topical finasteride are advised to consult a board-certified dermatologist or other qualified clinician to determine whether the medication is appropriate, to discuss dosing and to assess potential interactions or contraindications. Clinicians also recommend that men planning a family or women who are pregnant or may become pregnant avoid finasteride exposure and discuss alternative treatments with their provider.

The Post’s 2025 roundup aimed to help readers compare available topical finasteride options by listing active ingredients, typical timelines for expected results and common pros and cons reported by users. Dermatologists reiterated that while topical finasteride can reduce scalp DHT and slow hair loss with fewer systemic effects than oral therapy, careful clinical oversight remains important to ensure safe and effective treatment.